CLSA: Lowers ALI HEALTH (00241) target price to HK$3.7, maintains "Outperform" rating
Alibaba Health, nutritional supplements, JD Health
CLSA issued a research report stating that amid subsidy cuts and regulatory headwinds weighing on nutritional product sales, ALI HEALTH (00241) has lowered its FY2027 revenue outlook. The bank cut its target price on ALI HEALTH from HK$4.7 to HK$3.7, maintaining an "Outperform" rating.
CLSA lowered its FY2027-2028 adjusted net profit forecasts for the company by 6% to 7% to reflect weak nutritional product sales under regulatory pressure. Based on growth prospects and valuation, it prefers the more attractive JD HEALTH (06618).
Related Articles
.png)
HK Stock Market Move | CHERVON (02285) rises over 4%; the path for sustainable re-rating events is clear; Daiwa raises target price to HK$40.
J.P. Morgan: Reiterates "Overweight" rating on COSCO SHIPPING Energy Transportation (01138), recommends buying on dips.
HK Stock Market Move | Orders are fully booked. SICC Co.,Ltd.(02631) rises nearly 7%. Substrates may continue to increase in price in 2027.
HK Stock Market Move | CHERVON (02285) rises over 4%; the path for sustainable re-rating events is clear; Daiwa raises target price to HK$40.
J.P. Morgan: Reiterates "Overweight" rating on COSCO SHIPPING Energy Transportation (01138), recommends buying on dips.
HK Stock Market Move | Orders are fully booked. SICC Co.,Ltd.(02631) rises nearly 7%. Substrates may continue to increase in price in 2027.
